Welcome to our dedicated page for Clearmind Medicine Common Shares news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medicine Common Shares stock.
Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics. The company focuses on addressing widespread and under-treated health issues, particularly alcohol use disorder (AUD).
Currently, Clearmind's flagship compound, CMND-100, is in the spotlight. This MEAI-based (5-methoxy-2-aminoindane) formula has shown promising pre-clinical results in disrupting binge drinking behaviors without inducing hallucinations. The Israeli Ministry of Health has recently approved a Phase I/IIa clinical trial for CMND-100, marking a significant milestone in its development.
Clearmind's intellectual property portfolio is robust and growing, comprising eighteen patent families and 27 granted patents. Recent developments include nine new patent applications filed with the USPTO, highlighting compositions for treating alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. These efforts reflect the company's commitment to expanding and protecting its IP assets.
Collaborations play a crucial role in Clearmind's strategy. The company has entered exclusive licensing agreements with institutions such as the Hebrew University of Jerusalem, further enriching its portfolio with generation 3.0 psychedelic compounds aimed at treating addiction and mental health disorders. Additionally, Clearmind has initiated a groundbreaking partnership with Yissum Research Development Company for PTSD treatments.
Another key project is Clearmind's proprietary MEAI-based alcohol substitute beverage program. This ethanol-free alternative aligns with the growing global trend towards no- and low-alcohol consumption, offering a health-focused option for consumers.
Clearmind Medicine Inc. continues to execute its intellectual property and development strategies, positioning itself at the forefront of psychedelic-based medical treatments. The company’s shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under 'CWY0'.
For more information, please visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.
Clearmind Medicine Inc. (Nasdaq: CMND) has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, a MEAI-based treatment for alcohol use disorder (AUD). This approval marks the second clinical site for the multinational, multi-center trial, which will assess the safety, tolerability, and pharmacokinetics of CMND-100.
The trial will take place at Johns Hopkins University, Yale School of Medicine, and IMCA Center in Israel. Clearmind has already secured FDA approval for its Investigational New Drug (IND) application in the U.S. and approval from the Israeli Ministry of Health.
The primary endpoint of the trial is to determine the tolerable dose and evaluate the safety, pharmacokinetics, and pharmacodynamics of CMND-100. This milestone brings Clearmind closer to offering a potential solution for AUD, which is a major global health issue and the most common substance use disorder among people aged 12 and older in the U.S.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a pioneering combination therapy of Ibogaine and N-Acylethanolamines. This innovative treatment, developed in collaboration with SciSparc (Nasdaq: SPRC), aims to enhance safety and efficacy in mental health and addiction care.
Ibogaine, derived from the Tabernanthe iboga shrub, has shown promise in treating various substance use disorders. The combination with N-Acylethanolamines, including Palmitoylethanolamide (PEA), is expected to further improve the therapy's effectiveness and safety profile. This development underscores Clearmind's commitment to leadership in the psychedelics space and its focus on providing safe solutions for unmet mental health needs.
Clearmind Medicine Inc. (Nasdaq: CMND) has filed an international patent application for innovative psychedelic compounds designed to treat post-traumatic stress disorder (PTSD) and other mental health conditions. This application is part of Clearmind's collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The compounds were invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel.
The global PTSD treatment market, valued at $16.8 billion in 2023, is projected to reach $27.37 billion by 2033. Current PTSD treatments offer efficacy, and FDA-approved drugs often come with side effects. Clearmind aims to develop effective and safe next-generation psychedelic compounds to significantly improve patients' quality of life.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a novel combination treatment using MDMA and N-Acylethanolamines. This innovative approach aims to enhance safety and efficacy in mental health and addiction treatments. The patent is part of Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on integrating psychedelic molecules with N-Acylethanolamines, including Palmitoylethanolamide (PEA).
Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized that this combination therapy addresses FDA safety concerns about MDMA by potentially reducing its dosage while maintaining therapeutic efficacy. The company has filed thirteen patents related to this collaboration in various global jurisdictions, demonstrating their commitment to developing innovative treatments for mental health disorders and addictions.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of its patent application for innovative combinations of Ketamine and N-Acylethanolamines. This is a result of their ongoing collaboration with SciSparc (Nasdaq: SPRC). The companies are researching combination therapies integrating SciSparc's Palmitoylethanolamide (PEA) with Clearmind's psychedelic molecule MEAI, targeting addictions, weight loss, and mental health disorders.
To date, thirteen patents related to this collaboration have been filed globally. The goal is to develop treatments that maintain effectiveness while reducing doses and minimizing side effects. This approach could potentially address concerns associated with FDA-approved ketamine treatments, which require strict usage guidelines and close supervision due to potential side effects and abuse risks.
Clearmind Medicine Inc. (Nasdaq: CMND) has received a new patent approval from the United States Patent and Trademark Office for its MEAI-based binge behavior regulator program. The patent covers methods of regulating alcoholic beverage consumption and controlling binge behavior through the administration of amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the company's innovative psychedelic molecule.
This approval strengthens Clearmind's intellectual property portfolio, which now includes 29 granted patents across 19 patent families in key jurisdictions such as the U.S., Europe, China, and India. MEAI is a novel psychoactive molecule that reduces the desire to consume alcohol while providing a mild euphoric, alcohol-like experience. Clearmind's MEAI-based flagship treatment targets Alcohol Use Disorder (AUD) and weight loss, with potential applications in treating binge drinking.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the submission of an international patent application for generation 3.0 psychedelic compounds to treat mental disorders. This application is part of the company's ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent, developed by Prof. Dmitry Tsvelikhovsky, covers new psychedelic compounds, their preparation methods, and therapeutic uses.
The PCT submission allows Clearmind to proceed with national phase applications in major jurisdictions like the US, Europe, China, and India. Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized the potential of these advanced molecules to offer improved therapeutic options for patients with mental disorders. Clearmind, a clinical-stage psychedelic pharmaceutical biotech company, focuses on developing novel psychedelic-derived therapeutics for underserved health problems, including alcohol use disorder.
Clearmind Medicine Inc. (Nasdaq: CMND) announced promising results from a study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The research, led by Prof. Joseph Tam at the Hebrew University of Jerusalem, revealed significant findings:
1. Weight loss: MEAI reduced diet-induced obesity in mice, decreasing fat mass while preserving lean mass.
2. Improved metabolism: MEAI enhanced glycemic control by reducing hyperglycemia, glucose intolerance, and hyperinsulinemia.
3. Fatty liver disease: MEAI decreased fatty liver by lowering liver triglyceride and cholesterol levels.
4. Increased energy expenditure: MEAI boosted energy expenditure and fat utilization without affecting food consumption.
5. Activity: MEAI increased activity-specific energy expenditure without overstimulation.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, highlighted MEAI's potential as a breakthrough in obesity treatment, citing its efficacy, unique mechanism of action, and easy administration without food consumption constraints.
Clearmind Medicine Inc. (Nasdaq: CMND) successfully participated in the Psychedelic Medicine – Israel 2024 conference in Tel Aviv. CEO Adi Zuloff-Shani presented on '5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator', highlighting its potential in treating addiction-related disorders. Researchers from The Hebrew University of Jerusalem also presented an abstract on MEAI's ability to attenuate diet-induced obesity and related metabolic complications.
The conference provided Clearmind an opportunity to showcase its innovative therapies, engage with industry leaders, and expand its network of partners. Dr. Zuloff-Shani noted that the MEAI research garnered significant interest and acceptance among event participants, reinforcing Clearmind's position in the psychedelic-derived therapeutics field.
Clearmind Medicine Inc. (Nasdaq: CMND) has partnered with JS First Sdn. Bhd to source global manufacturers and distributors for its MEAI-based alcohol substitute beverages. This strategic move follows Clearmind's recent entry into the non-alcoholic beverage market with its patented, neurologically active novel alcohol replacement drink. The beverage aims to offer the social benefits of alcohol without negative health impacts.
JS First will conduct research on manufacturing and licensing rights in foreign markets, identify manufacturing partners, and establish relationships with distributors globally. The collaboration targets markets in the U.S., Europe, Africa, and Southeast Asia. According to IWSR, the no- and low-alcohol market is valued at over $13 billion and is forecast to grow at a CAGR of +6% between 2023 and 2027.
FAQ
What is the current stock price of Clearmind Medicine Common Shares (CMND)?
What is the market cap of Clearmind Medicine Common Shares (CMND)?
What is Clearmind Medicine Inc.'s primary area of focus?
What is CMND-100?
What recent clinical developments has Clearmind made?
What are the key features of Clearmind's intellectual property portfolio?
What strategic collaborations has Clearmind entered into?
What is Clearmind's MEAI-based alcohol substitute beverage program?
Where are Clearmind's shares traded?
How can I contact Clearmind Medicine Inc. for more information?
What is Clearmind's approach to intellectual property?
How does Clearmind ensure the safety of its novel compounds?
